ReviewCurrent oncology (Toronto, Ont.)2024
A Comprehensive Review and Insights into the New Entity of Differentiated High-Grade Thyroid Carcinoma.
Review in Current oncology (Toronto, Ont.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer.Thyroid : official journal of the American Thyroid Association · 2025Guideline
- Aggressive Thyroid Carcinomas Clinical and Molecular Features: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- Squamous dedifferentiation and differentiated high-grade transformation of papillary thyroid carcinoma in metastatic lymph nodes: Two cases and literature review.Radiology case reports · 2026Article
- Integrating Digital Ki-67 Labeling Index and K-TIRADS for Malignancy Risk Stratification in Thyroid Core Needle Biopsies.Cancers · 2026Article
- Re-Analyzing Differentiated High-Grade Thyroid Carcinoma and Elevated Ki-67 Proliferation: A Single-Center Retrospective Study.Journal of clinical medicine · 2026Article
- P53 loss and BRAF V600E mutation suggest potentially divergent pathways to aggressiveness in high grade differentiated thyroid carcinoma.Discover oncology · 2026Article
- Clinicopathological profile of high-grade differentiated thyroid carcinoma in an Indonesian tertiary hospital.Journal of pathology and translational medicine · 2026Article
- Therapeutic Potential of Tyrosine Kinase Inhibitors in Advanced Thyroid Cancer.Current oncology reports · 2026Review
- Synchronous metastatic differentiated high-grade thyroid carcinoma in lymph node from classic papillary thyroid carcinoma: a case report and literature review.Frontiers in oncology · 2026Article
- Clinicopathological, proliferative, molecular, and prognostic characteristics of differentiated high-grade thyroid carcinoma: a multicenter retrospective study.Frontiers in oncology · 2026Article
- Diagnostic Challenges, Prognostic Assessment, and Treatment Strategies in High-Grade Differentiated Thyroid Carcinoma.Endocrinology and metabolism (Seoul, Korea) · 2025Review
- HighCancers · 2025Article
- Radiofrequency Ablation for Locoregional Structural Incomplete Response in Differentiated Thyroid Cancer: Initial Experience in Greece.Biomedicines · 2025Article
- CouldDiagnostics (Basel, Switzerland) · 2024Article
- Aggressive Types of Malignant Thyroid Neoplasms.Journal of clinical medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Differentiated high-grade thyroid carcinoma (DHGTC) is a new subset within the spectrum of thyroid malignancies. This review aims to provide a comprehensive overview of DHGTC, focusing on its historical perspective, diagnosis, clinical characteristics, molecular profiles, management, and prognosis. DHGTC demonstrates an intermediate prognosis that falls between well-differentiated thyroid carcinoma and anaplastic thyroid carcinoma. Previously unenumerated, this entity is now recognized for its significant impact. Patients with DHGTC often present at an older age with advanced disease and exhibit aggressive clinical behavior. Molecularly, DHGTC shares similarities with other thyroid malignancies, harboring driver mutations such as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.